Does Rallies show 13F holders for INBX?

Yes. Rallies tracks hedge fund and 13F ownership data for INBX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INBX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INBX. It does not provide personalized investment advice.

INBX (Inhibrx Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Inhibrx Biosciences, Inc. Common Stock (INBX) is a publicly traded Healthcare sector company. As of May 21, 2026, INBX trades at $106.96 with a market cap of $1.55B and a P/E ratio of -13.02. INBX moved +0.42% today. Year to date, INBX is +43.09%; over the trailing twelve months it is +741.70%. Its 52-week range spans $10.81 to $155.29. Analyst consensus is buy with an average price target of $277.50. Rallies surfaces INBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INBX stock?

Hedge funds tracked by Rallies that own INBX include Viking Global and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inhibrx Biosciences, Inc. Common Stock.

INBX Key Metrics

Key financial metrics for INBX
Metric	Value
Price	$106.96
Market Cap	$1.55B
P/E Ratio	-13.02
EPS	$-8.39
Dividend Yield	0.00%
52-Week High	$155.29
52-Week Low	$10.81
Volume	3
Avg Volume	0
Revenue (TTM)	$1.30M
Net Income	$-130.19M
Gross Margin	0.00%

Top Hedge Funds Holding INBX

Viking Global holds 1.44M shares of INBX, changed +0.00% as of Mar 31, 2026.
Mangrove Partners holds 5.53K shares of INBX, changed +0.00% as of Mar 31, 2026.

Latest INBX News

Inhibrx Raises Cash to $161.7M, Narrows Loss and Reveals Phase II Data — May 14, 2026
Inhibrx Shows 20% ORR and 5.5-Month PFS in Late-Line Colorectal Cancer Study — Apr 21, 2026
Inhibrx Schedules April 21 Webcast for Ozekibart CRC Phase 1/2 Update — Apr 20, 2026
Inhibrx Reports FY2025 Net Loss, $124M Cash and $75M Loan, Plans 2026 BLA — Mar 19, 2026

Recent INBX Insider Trades

VIKING GLOBAL INVESTORS LP sold 308.64K (~$9.95M) on Oct 7, 2025.
VIKING GLOBAL INVESTORS LP sold 16.32K (~$526.16K) on Oct 7, 2025.
VIKING GLOBAL INVESTORS LP sold 25.04K (~$807.60K) on Oct 7, 2025.

INBX Analyst Consensus

2 analysts cover INBX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $277.50.

Common questions about INBX

Who owns INBX stock?: Hedge funds tracked by Rallies that own INBX include Viking Global and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Inhibrx Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for INBX?: Yes. Rallies tracks hedge fund and 13F ownership data for INBX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INBX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INBX. It does not provide personalized investment advice.